CLINUVEL Newsletter – January 2019
15 January 2019
Dear patients, shareholders, friends,
I wish you all a year in good physical and spiritual health, and a year in which we anticipate further progress of SCENESSE ® (afamelanotide 16mg)1 and CLINUVEL’s other products and activities. We look to a rather full year of events affecting CLINUVEL in one way or the other: firstly, the direct drivers such as US regulatory, European clinical, and UK geopolitical (read Brexit); and secondly, the indirect events such as the domestic financial regulatory reviews (Australian’s Royal Commission report on 1 February), and the release of US key financial data. We are looking forward to 2019, undoubtedly requiring us to navigate all known and new challenges which lie ahead of us and which, by now, has become part of our team’s DNA: anticipating and reacting to resistance, obstacles, and legislative and regulatory changes. I wish my team and all of our audiences a successful year in optima forma.